



ANDA 206032

ANDA APPROVAL

Mylan Pharmaceuticals Inc.  
781 Chestnut Ridge Road  
P.O. Box 4310  
Morgantown, WV 26504  
Attention: Joseph J. Sobecki  
Vice President, Regulatory Affairs

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), for Memantine Hydrochloride Extended-Release Capsules, 7 mg, 14 mg, 21 mg, and 28 mg.

Reference is also made to the tentative approval letter issued by this office on November 30, 2015, and to your amendment dated April 6, 2016.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. **Accordingly the ANDA is approved**, effective on the date of this letter. The Office of Bioequivalence has determined your Memantine Hydrochloride Extended-Release Capsules, 7 mg, 14 mg, 21 mg, and 28 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Namenda XR of Forest Laboratories Inc. (Forest).

Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your ANDA. The “interim” dissolution specifications are as follows:

USP Apparatus:	1 (basket)
Rotational Speed:	100 rpm
Temperature:	37°C ± 0.5°C
Media:	pH 1.2 Buffer, Simulated Gastric Fluid without enzyme
Volume:	900 mL
Specifications	1 hr: NMT (b) (4)%; 4 hrs (b) (4)%; 8 hrs: (b) (4)%; 16 hrs: NLT (b) (4)%

The “interim” dissolution test(s) and tolerances should be finalized by submitting dissolution data for the first three production size batches. Data should be submitted as a Special Supplement – Changes Being Effected when there are no revisions to the “interim” specifications or when the final specifications are tighter than the “interim” specifications. In all other instances, the information should be submitted in the form of a Prior Approval Supplement.

The reference listed drug RLD upon which you have based your ANDA, Forest's Namenda XR Capsules, 7 mg, 14 mg, 21 mg, and 28 mg, is subject to periods of patent protection. The following patents and expiration dates (with pediatric extension added) are currently listed in the agency's publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book"):

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
8,168,209 (the '209 patent)	May 22, 2026
8,173,708 (the '708 patent)	May 22, 2026
8,283,379 (the '379 patent)	May 22, 2026
8,329,752 (the '752 patent)	May 22, 2026
8,362,085 (the '085 patent)	May 22, 2026
8,598,233 (the '233 patent)	May 22, 2026 (28 mg only)
8,039,009 (the '009 patent)	September 24, 2029

Your ANDA contains paragraph IV certifications to each of the patents<sup>1</sup> under section 505(j)(2)(A)(vii)(IV) of FD&C Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Memantine Hydrochloride Extended-Release Capsules, 7 mg, 14 mg, 21 mg, and 28 mg, under this ANDA. You have notified the agency that Mylan Pharmaceuticals Inc. (Mylan) complied with the requirements of section 505(j)(2)(B) of FD&C Act, and that litigation was initiated against Mylan for infringement of the '703, '009, '209, '708, '379, '752, '085, and '233 patents within the statutory 45-day period in the United States District Court for the District of Delaware [Forest Laboratories, Inc., Forest Laboratories Holdings, LTD., Merz Pharma GMBH & Co. KGAA, Pharmaceuticals GMBH, and Adamas Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., Civil Action No. 1: 14-cv-00508-LPS]. You have further notified the Agency that the case has been dismissed.

Under section 506A of FD&C Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of FD&C Act.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

---

<sup>1</sup> The agency notes that the '233 patent was listed in the Orange Book after submission of your ANDA. Litigation, if any, with respect to this patent would not create a statutory stay of approval.

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Office of Prescription Drug Promotion with a completed Form FDA 2253 at the time of their initial use.

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1<sup>st</sup> of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the Federal Register notice announcing facility fee amounts. All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

*{See appended electronic signature page}*

Carol A. Holquist, RPh  
Acting Deputy Director  
Office of Regulatory Operations  
Office of Generic Drugs  
Center for Drug Evaluation and Research



Carol  
Holquist

Digitally signed by Carol Holquist  
Date: 9/28/2016 12:13:43PM  
GUID: 508da712000293e0f6d8acfd3c5e67fe

